Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 16 Prostatic Neoplasms 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia 2 Healthy Participants 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer Metastatic 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1

Interventions

Nivolumab 15 Surveys and Questionnaires 7 Ipilimumab 7 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 relatlimab 3 Vorinostat 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 regorafenib 2 apatinib 2 abemaciclib 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Dasatinib 2 Cisplatin 2 Chlorogenic Acid 2 Capecitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02338622 2024-09-26

ComPAKT

Royal Marsden NHS Foundation Trust

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡